• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症中的免疫代谢:系统视角

Immunometabolism in cancer: a systemic perspective.

作者信息

Moretti Helena, Cioccoloni Giorgia, Perucha Esperanza

机构信息

Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, King's College London & Centre for Rheumatic Diseases, King's College London, London, United Kingdom.

School of Food Science & Nutrition, University of Leeds, Leeds, United Kingdom.

出版信息

Front Immunol. 2025 Oct 8;16:1656776. doi: 10.3389/fimmu.2025.1656776. eCollection 2025.

DOI:10.3389/fimmu.2025.1656776
PMID:41132655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12540421/
Abstract

Cancer incidence is increasing, becoming a significant public health concern. Cancer arises from the uncontrolled division of cells that cannot be restrained by the anti-tumour response mounted by the immune system. Both tumour and immune cells require high levels of energy in the form of ATP and synthesis of macromolecules to support differentiation and proliferation. To support these metabolic demands, adaptations at the cell, tissue and systemic level are required. Here, we take a systemic perspective to summarise the energetic needs of the anti-tumour response and how metabolic overload and obesity affects these processes. We describe how immunotherapies that aim to reverse immune cell exhaustion have unexpected effects depending on the metabolic background of the patient and finally we propose the use of this knowledge to advance current cancer prevention and treatment strategies.

摘要

癌症发病率正在上升,成为一个重大的公共卫生问题。癌症源于细胞的不受控制的分裂,而这种分裂无法被免疫系统发起的抗肿瘤反应所抑制。肿瘤细胞和免疫细胞都需要高水平的以三磷酸腺苷(ATP)形式存在的能量以及大分子的合成来支持分化和增殖。为了满足这些代谢需求,需要在细胞、组织和系统层面进行适应性调整。在这里,我们从系统的角度总结抗肿瘤反应的能量需求,以及代谢过载和肥胖如何影响这些过程。我们描述了旨在逆转免疫细胞耗竭的免疫疗法如何根据患者的代谢背景产生意想不到的效果,最后我们提出利用这些知识来推进当前的癌症预防和治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/2fe0cf3a3e58/fimmu-16-1656776-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/28eb0d1f0d91/fimmu-16-1656776-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/bd1b4308834f/fimmu-16-1656776-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/f04901be2cb8/fimmu-16-1656776-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/2fe0cf3a3e58/fimmu-16-1656776-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/28eb0d1f0d91/fimmu-16-1656776-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/bd1b4308834f/fimmu-16-1656776-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/f04901be2cb8/fimmu-16-1656776-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/581f/12540421/2fe0cf3a3e58/fimmu-16-1656776-g004.jpg

相似文献

1
Immunometabolism in cancer: a systemic perspective.癌症中的免疫代谢:系统视角
Front Immunol. 2025 Oct 8;16:1656776. doi: 10.3389/fimmu.2025.1656776. eCollection 2025.
2
Cancer, obesity and immunometabolism - Connecting the dots.癌症、肥胖与免疫代谢——理清其中的关联。
Cancer Lett. 2018 Mar 28;417:11-20. doi: 10.1016/j.canlet.2017.12.019. Epub 2017 Dec 16.
3
Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes.肥胖与 CD8 T 细胞代谢:对肿瘤免疫及癌症免疫治疗效果的影响。
Immunol Rev. 2020 May;295(1):203-219. doi: 10.1111/imr.12849. Epub 2020 Mar 10.
4
Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy.
Mol Cancer. 2025 Oct 8;24(1):249. doi: 10.1186/s12943-025-02460-1.
5
Immunometabolism: A new target for improving cancer immunotherapy.免疫代谢:改善癌症免疫疗法的新靶点。
Adv Cancer Res. 2019;143:195-253. doi: 10.1016/bs.acr.2019.03.004. Epub 2019 Apr 17.
6
Obesity induced T cell dysfunction and implications for cancer immunotherapy.肥胖诱导的 T 细胞功能障碍及其对癌症免疫治疗的影响。
Curr Opin Immunol. 2018 Apr;51:181-186. doi: 10.1016/j.coi.2018.03.012. Epub 2018 Apr 11.
7
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy.免疫细胞重编程中的代谢检查点:为癌症治疗重新调整免疫代谢
Mol Cancer. 2025 Aug 2;24(1):210. doi: 10.1186/s12943-025-02407-6.
8
Targeting immunometabolism of neoplasms by interleukins: A promising immunotherapeutic strategy for cancer treatment.通过白细胞介素靶向肿瘤的免疫代谢:癌症治疗有前景的免疫治疗策略。
Cancer Lett. 2021 Oct 10;518:94-101. doi: 10.1016/j.canlet.2021.06.013. Epub 2021 Jun 18.
9
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.针对癌症中CD8 T细胞和自然杀伤细胞的代谢功能障碍
Nat Rev Drug Discov. 2025 Mar;24(3):190-208. doi: 10.1038/s41573-024-01098-w. Epub 2024 Dec 12.
10
Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective.通过纳米医学重编程免疫抑制性肿瘤微环境:免疫代谢观点。
EBioMedicine. 2024 Sep;107:105301. doi: 10.1016/j.ebiom.2024.105301. Epub 2024 Aug 22.

本文引用的文献

1
Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR/MSI-H colorectal cancer.身体组成对错配修复缺陷/微卫星高度不稳定结直肠癌新辅助免疫治疗病理反应的影响
Front Immunol. 2025 May 30;16:1589869. doi: 10.3389/fimmu.2025.1589869. eCollection 2025.
2
Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer.模拟扩大免疫检查点抑制剂作为晚期非小细胞肺癌单药治疗可及性的潜在财务影响。
EClinicalMedicine. 2025 May 24;84:103261. doi: 10.1016/j.eclinm.2025.103261. eCollection 2025 Jun.
3
Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.
代谢和营养紊乱对非小细胞肺癌放疗与免疫治疗协同作用的影响。
BMC Cancer. 2025 May 27;25(1):948. doi: 10.1186/s12885-025-14278-7.
4
High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer and models.高剂量抗坏血酸与抗PD1疗法在非小细胞肺癌及模型中具有协同作用。
Front Immunol. 2025 Jan 17;15:1512605. doi: 10.3389/fimmu.2024.1512605. eCollection 2024.
5
Association of Body Composition Parameters with the Short- and Long-Term Efficacy of Neoadjuvant Immunotherapy Combined with Chemotherapy in Advanced Gastric Cancer.体成分参数与新辅助免疫治疗联合化疗在晚期胃癌中的短期和长期疗效的关联
Nutr Cancer. 2025;77(4-5):455-464. doi: 10.1080/01635581.2025.2455762. Epub 2025 Jan 26.
6
Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer.他汀类药物与免疫检查点抑制剂联合使用及非小细胞肺癌患者的生存率
Clin Lung Cancer. 2025 May;26(3):201-209. doi: 10.1016/j.cllc.2024.12.008. Epub 2024 Dec 25.
7
Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types.胰高血糖素样肽-1受体(GLP1R)表达对癌症生存的预后影响及其对GLP-1R激动剂治疗的意义:一项跨多种肿瘤类型的综合分析
Geroscience. 2025 Jan 8. doi: 10.1007/s11357-024-01494-5.
8
Concomitant Statin Use and Survival in Patients With Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis.癌症患者在接受免疫检查点抑制剂治疗时同时使用他汀类药物与生存率:一项荟萃分析。
JCO Oncol Pract. 2025 Jan 7:OP2400583. doi: 10.1200/OP-24-00583.
9
Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.胰高血糖素样肽-1激动剂可降低接受免疫检查点抑制剂治疗的癌症患者的心血管事件发生率。
Eur J Cancer. 2025 Feb 5;216:115170. doi: 10.1016/j.ejca.2024.115170. Epub 2024 Dec 11.
10
GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors.胰高血糖素样肽-1受体激动剂促进表达胰高血糖素样肽-1受体的神经内分泌肿瘤细胞增殖。
Surgery. 2025 Mar;179:108943. doi: 10.1016/j.surg.2024.09.052. Epub 2024 Dec 10.